Over 140 Things you need to know about your BMT or SCT
The latest read is this book by Mark Patton, in his view The World’s Most Transplanted Person, having been transplanted five times!
The book contains over 140 invaluable tips to help transplant patients get through their procedures, it may help transplant candidates decide if BMTs or PBSCTs are their best treatment option, it lists dozens of sources of free material and information and it has a transplant Resource Directory with 100 organizations that offer support and encouragement.
A portion of the proceeds from the sale the publication will be donated to The Bone Marrow Foundation to help patients in need of financial assistance with their bone marrow transplants or stem cell transplants.
You can learn more at Mark's web site www.bmtresources.org
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
